How Much Longer Will We Put Up With $100,000 Cancer Drugs?

Paul Workman; Giulio F Draetta; Jan H M Schellens; René Bernards

doi:10.1016/j.cell.2017.01.034

How Much Longer Will We Put Up With $100,000 Cancer Drugs?

Cell. 2017 Feb 9;168(4):579-583. doi: 10.1016/j.cell.2017.01.034.

Authors

Paul Workman¹, Giulio F Draetta², Jan H M Schellens³, René Bernards⁴

Affiliations

¹ Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK.
² Department of Genomic Medicine and Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
³ Division of Clinical Pharmacology, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands.
⁴ Division of Molecular Carcinogenesis and Cancer Genomics Centre Netherlands, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands. Electronic address: r.bernards@nki.nl.

PMID: 28187281
DOI: 10.1016/j.cell.2017.01.034

Abstract

The spiraling cost of new drugs mandates a fundamentally different approach to keep lifesaving therapies affordable for cancer patients. We call here for the formation of new relationships between academic drug discovery centers and commercial partners, which can accelerate the development of truly transformative drugs at sustainable prices.

MeSH terms

Antineoplastic Agents / economics*
Antineoplastic Agents / therapeutic use
Drug Approval
Drug Costs* / legislation & jurisprudence
Drug Discovery
Health Care Costs
Humans
Neoplasms / drug therapy*
United States

Substances

Antineoplastic Agents

Abstract

MeSH terms

Substances

Grants and funding